February 2nd Update

The AP has requested a timeseries dataset reporting daily counts for distributed and administered vaccines in the U.S. from the CDC. In the absence of that dataset, we are storing daily snapshots of the cumulative counts provided by the CDC COVID Data Tracker and compiling a timeseries dataset here. This process has captured cumulative counts going back to January 4th and daily counts of new doses administered and distributed going back to January 5th. The timeseries dataset also includes seven-day rolling average calculations for the daily metrics.

We have identified a few instances of decreasing cumulative counts in this timeseries, which result in single-day negative counts. We are treating these instances as corrections, and include the negative counts in the rolling averages.

We are investigating the cumulative count decreases and will update the timeseries dataset if necessary with additional information from the CDC. When the CDC provides its own timeseries dataset we will make that available here.

Overview

The AP is using data provided by the Centers for Disease Control and Prevention to report vaccine doses distributed and administered in the United States.

This data is from the CDC's COVID Data Tracker, which is updated daily. However, keep in mind that healthcare providers can report doses to federal, state, territorial, and local agencies up to 72 hours after doses are administered.

To learn more about AP's data journalism capabilities for publishers, corporations and financial institutions, go here or email kromano@ap.org.

Interactive

The AP has designed an interactive map to track COVID-19 vaccine counts reported by The CDC. @(https://interactives.ap.org/embeds/TUVpf/14/)

Interactive Embed Code

<iframe title="Tracking US COVID vaccinations" aria-label="Map" id="datawrapper-chart-TUVpf" src="https://interactives.ap.org/embeds/TUVpf/14/" scrolling="no" width="100%" style="border:none" height="548"></iframe><script type="text/javascript">!function(){"use strict";window.addEventListener("message",(function(a){if(void 0!==a.data["datawrapper-height"])for(var e in a.data["datawrapper-height"]){var t=document.getElementById("datawrapper-chart-"+e)||document.querySelector("iframe[src*='"+e+"']");t&&(t.style.height=a.data["datawrapper-height"][e]+"px")}}))}();</script>

Caveats

From The CDC: - Numbers reported on CDC’s website are validated through a submission process with each jurisdiction and may differ from numbers posted on other websites. - Differences between reporting jurisdictions and CDC’s website may occur due to the timing of reporting and website updates. - The process used for reporting doses distributed or people vaccinated displayed by other websites may differ.

Overall US COVID-19 Vaccine deliveries and administration data at national and jurisdiction level. Data represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities.

After October 13, 2022, this dataset will no longer be updated as the related CDC COVID Data Tracker site was retired on October 13, 2022.

This dataset contains historical trends in vaccinations and cases by age group, at the US national level. Data is stratified by at least one dose and fully vaccinated. Data also represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases

This site provides historical data beginning June 14, 2023, for the visualization presented on COVID-19 Data Tracker’s “Vaccinations in the United States" site titled “US COVID-19 Vaccine Doses Delivered by Vaccine Type” Definition for Distributed: Cumulative number of COVID-19 updated vaccine doses distributed in the United States. CDC is no longer reporting metrics for Johnson & Johnson, and the original Pfizer and Moderna vaccines. Data represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases

This site provides historical data beginning June 22, 2022, for the visualization presented on COVID-19 Data Tracker’s “Vaccinations in the United States” site titled “Primary Series Completion, Booster Dose Eligibility, and Booster Dose Receipt by Age, United States”. Fully Vaccinated / Completed Primary Series: For surveillance purposes, COVID Data Tracker counts people as being "fully vaccinated" or as having "completed a primary series" if they received two doses on different days (regardless of time interval) of the two-dose mRNA series or received one dose of a single-dose vaccine. When the vaccine manufacturer is not reported, the recipient is considered fully vaccinated with two doses.First Booster Dose:  For surveillance purposes, the count and percentage of people who received a first booster dose includes anyone who is fully vaccinated and has received another dose of COVID-19 vaccine since August 13, 2021. This includes people who received a first booster dose and people who received an additional primary series dose as this metric does not distinguish if the recipient is  immunocompromised and received an additional dose. First booster dose eligibility: CDC counts people as being " eligible for a first booster dose" if it has been at least 5 months since completion of a Pfizer-BioNTech or Moderna primary series or at least 2 months since receipt of a Janssen (Johnson & Johnson) singe-dose vaccine. Second Booster Dose:For surveillance purposes, the count and percentage of people who received a second booster dose includes anyone who is fully vaccinated and has received two subsequent doses of COVID-19 vaccine since August 13, 2021. This includes people who received two booster doses and people who received one additional dose and one booster dose.  The count of people who received a second booster dose and the percentage of people with a first booster who received a second booster dose does not account for whether a person is immunocompromised or time interval since first booster dose. Second booster dose eligibility: CDC counts people as being  "eligible for a second booster dose"  if it has been at least 4 months since receiving a first booster dose. Limitations to counting people with a second booster dose: Due to the aggregate vaccination record reporting method used by Idaho for its residents under the age of 18 years and by Texas for all its residents, CDC counts all 4th doses received by these populations as a second booster dose. This includes immunocompromised individuals who received a three-dose primary series and only one booster dose. This limitation may lead to an undercount of people who received the single-dose J&J/Janssen vaccine as their primary series and two booster doses. Data represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities.

Context

This dataset provides State-by-state data on United States COVID-19 vaccinations between 20 December of 2020 and 12 January of 2022. Data is taken daily by the United States Centers for Disease Control and Prevention

Columns

us_vaccinations File

- location: State name.

- date: date of the case.

- total_vaccinations: total number of doses administered. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses). If a person receives one dose of the vaccine, this metric goes up by 1. If they receive a second dose, it goes up by 1 again.

- total_vaccinations_per_hundred: total_vaccinations per 100 people in the total population of the state.

- daily_vaccinations_raw: daily change in the total number of doses administered. It is only calculated for consecutive days. This is a raw measure provided for data checks and transparency, but we strongly recommend that any analysis on daily vaccination rates be conducted using daily_vaccinations instead.

- daily_vaccinations: new doses administered per day (7-day smoothed). For countries that don't report data on a daily basis, we assume that doses changed equally on a daily basis over any periods in which no data was reported. This produces a complete series of daily figures, which is then averaged over a rolling 7-day window. An example of how we perform this calculation can be found here.

- daily_vaccinations_per_million: daily_vaccinations per 1,000,000 people in the total population of the state.

- people_vaccinated: total number of people who received at least one vaccine dose. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same.

- people_vaccinated_per_hundred: people_vaccinated per 100 people in the total population of the state.

- people_fully_vaccinated: total number of people who received all doses prescribed by the vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1.

- people_fully_vaccinated_per_hundred: people_fully_vaccinated per 100 people in the total population of the state.

- total_distributed: cumulative counts of COVID-19 vaccine doses recorded as shipped in CDC's Vaccine Tracking System.

- total_distributed_per_hundred: cumulative counts of COVID-19 vaccine doses recorded as shipped in CDC's Vaccine Tracking System per 100 people in the total population of the state.

- share_doses_used: share of vaccination doses administered among those recorded as shipped in CDC's Vaccine Tracking System.

Data as of: May 18, 2021

Weekly updates have finished with the June 28th update. This dataset contains aggregate data by zip code of residence and by ethnicity for individuals that received a COVID vaccination. Data includes counts of individuals who received a vaccine dose that provides partial coverage against the disease and counts of individuals that received a vaccine dose that provides full coverage against the disease. Suppression applies for quantities less than 5. Data only includes information reported to PA-SIIS, the Pennsylvania Statewide Immunization Information System.
Effective 7/9/2021, the COVID-19 Vaccine Dashboard is updated to more accurately reflect the number of people who are partially and fully vaccinated in each county outside of Philadelphia, along with the demographics of those receiving vaccine. For state-to-state comparisons refer to the CDC vaccine data tracker located here: https://covid.cdc.gov/covid-data-tracker/#county-view

With the federal COVID-19 Public Health Emergency ending on May 11th, the Montana Department of Health & Human Services will discontinue weekly updates to the COVID-19 case tracking and vaccine map dashboards and feature services. The last weekly update to the dashboards will take place on May 5th, 2023. After this final data update, the dashboards will remain available to viewers until July 14th, 2023. However, it should be noted that data will not be current after May 5th, 2023.To access up-to-date COVID-19 data for Montana after 5/11/2023, visit the CDC’s COVID Data Tracker website: https://covid.cdc.gov/covid-data-trackerThe Montana COVID-19 Vaccination Data web service hosts COVID-19 vaccination statistics for the state of Montana. The Department of Health and Human Service tabulates vaccination data and then gives the data to the Montana State Library to update the number of vaccine doses administered (daily) and Montana county vaccination data (weekly). Montana public health agencies and the Governor's Coronavirus task Force are actively working to limit the spread of novel coronavirus in Montana. The Montana State Library is aiding this effort by geo-enabling public health information and emergency response data to help decision-makers, State Emergency Coordination Center and the Governor's Coronavirus Task Force understand the spread of the disease.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Updated (Bivalent) Booster Status. Click 'More' for important dataset description and footnotes

Webpage: https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status

Dataset and data visualization details:

These data were posted and archived on May 30, 2023 and reflect cases among persons with a positive specimen collection date through April 22, 2023, and deaths among persons with a positive specimen collection date through April 1, 2023. These data will no longer be updated after May 2023.

Vaccination status: A person vaccinated with at least a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. A person vaccinated with a primary series and a monovalent booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and at least one additional dose of any monovalent FDA-authorized or approved COVID-19 vaccine on or after August 13, 2021. (Note: this definition does not distinguish between vaccine recipients who are immunocompromised and are receiving an additional dose versus those who are not immunocompromised and receiving a booster dose.) A person vaccinated with a primary series and an updated (bivalent) booster dose had SARS-CoV-2 RNA or antigen detected in a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and an additional dose of any bivalent FDA-authorized or approved vaccine COVID-19 vaccine on or after September 1, 2022. (Note: Doses with bivalent doses reported as first or second doses are classified as vaccinated with a bivalent booster dose.) People with primary series or a monovalent booster dose were combined in the “vaccinated without an updated booster” category.

Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Per the interim guidance of the Council of State and Territorial Epidemiologists (CSTE), this should include persons whose death certificate lists COVID-19 disease or SARS-CoV-2 as the underlying cause of death or as a significant condition contributing to death. Rates of COVID-19 deaths by vaccination status are primarily reported based on when the patient was tested for COVID-19. In select jurisdictions, deaths are included that are not laboratory confirmed and are reported based on alternative dates (i.e., onset date for most; or date of death or report date, where onset date is unavailable). Deaths usually occur up to 30 days after COVID-19 diagnosis.

Participating jurisdictions: Currently, these 24 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Colorado, District of Columbia, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (NY), North Carolina, Rhode Island, Tennessee, Texas, Utah, and West Virginia; 23 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 48% of the total U.S. population and all ten of the Health and Human Services Regions. This list will be

AUTHORITATIVE with significant views when in production.Doses distributed and people initiating vaccination (1st dose received) are for both Moderna and Pfizer BioNTech COVID-19 vaccine and reflect current data available as of 9:00am ET on the day of reporting. Data will be regularly updated on Monday, Wednesday and Friday. Updates will occur the following day when reporting coincides with a federal holiday.Healthcare providers report doses to federal, state, territorial, and local agencies up to 72 hours after administration. There may be additional lag for data to be transmitted from the federal, state, territorial, or local agency to CDC. A large difference between the number of doses distributed and the number of people initiating vaccination is expected at this point in the COVID vaccination program due to several factors, including delays in reporting of administered doses and management of available vaccine stocks by jurisdictions and federal pharmacy partners.Numbers reported on CDC’s website are validated through a submission process with each jurisdiction and may differ from numbers posted on other websites. Differences between reporting jurisdictions and CDC’s website may occur due to the timing of reporting and website updates. The process used for reporting doses distributed or people vaccinated displayed by other websites may differ.When the “Rate per 100,000” metric is selected for both doses distributed and people initiating vaccination (1st dose received), federal entities will display as n/a because population-based rates are not applicable. Doses distributed and administered for federal entities will display when the “Counts” metric is selected.Doses distributed are cumulative counts of COVID-19 vaccine doses recorded as shipped in the Centers for Disease Control and Prevention’s (CDC) Vaccine Tracking System (VTrckS) since December 13, 2020.People initiating vaccination (1st dose received) are cumulative counts of individual COVID-19 vaccine first doses administered as reported to the CDC by state, territorial, and local public health agencies and four federal entities (Bureau of Prisons, Department of Defense, Indian Health Service, and Veterans Health Administration) since December 14, 2020. For information pertaining to Department of State’s COVID-19 vaccination program, please contact the Office of Press Operations at PAPressDuty@state.gov. Veterans Health Administration totals include employees, veteran patients, and other federal partners vaccinated by VHA.Long-term care facility (LTCF) data is a subset of the overall national data, specific to the Federal Pharmacy Partnership for Long-term Care (LTC) Program, and primarily includes skilled nursing and assisted living facilities. Doses distributed refers to doses distributed to pharmacy partners to administer onsite at LTCFs, and people initiating vaccination (1st dose received) includes both LTCF residents and staff vaccinated through the program. This data does not include doses distributed and administered to LTCF residents and staff outside the Federal Pharmacy Partnership Program. Vaccine administration through the federal program launched nationally on December 21st for Pfizer vaccine and on December 28th for Moderna vaccine. As of December 29, 2020, a total of 52 jurisdictions have started the program. Program start dates vary based on the jurisdiction. A difference between the number of doses distributed to pharmacy partners and the number of people initiating vaccination is expected because jurisdictions are transferring doses to pharmacy partners in advance to prepare for vaccination clinics in subsequent weeks.Rates per 100,000 population use the U.S. Census Bureau 2019 American Community Survey 1-year population estimates. 2018 population estimates are used for American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Palau, Republic of Marshall Islands, and United States Virgin Islands.

Household Pulse Survey (HPS): HPS is a rapid-response survey of adults ages ≥18 years led by the U.S. Census Bureau, in partnership with seven other federal statistical agencies, to measure household experiences during the COVID-19 pandemic. Detailed information on probability sampling using the U.S. Census Bureau’s Master Address File, questionnaires, response rates, and bias assessment is available on the Census Bureau website (https://www.census.gov/data/experimental-data-products/household-pulse-survey.html). Data from adults ages ≥18 years and older are collected by a 20-minute online survey from randomly sampled households stratified by state and the top 15 metropolitan statistical areas (MSAs). Data are weighted to represent total persons ages 18 and older living within households and to mitigate possible bias that can result from non-responses and incomplete survey frame. Data from adults ages ≥18 years and older are collected by 20-minute online survey from randomly sampled households stratified by state and the top 15 metropolitan statistical areas (MSAs). For more information on this survey, see https://www.census.gov/programs-surveys/household-pulse-survey.html. Data are weighted to represent total persons ages 18 and older living within households and to mitigate possible bias that can result from non-responses and incomplete survey frame. Responses in the Household Pulse Survey (https://www.census.gov/programs-surveys/household-pulse-survey.html) are self-reported. Estimates of vaccination coverage may differ from vaccine administration data reported at COVID-19 Vaccinations in the United States (https://covid.cdc.gov/covid-data-tracker/#vaccinations).

Weekly updates have finished with the June 28th update. This dataset contains aggregate data by zip code of residence and by gender for individuals that received a COVID vaccination. Data includes counts of individuals who received a vaccine dose that provides partial coverage against the disease and counts of individuals that received a vaccine dose that provides full coverage against the disease. Suppression applies for quantities less than 5.
Effective 7/9/2021, the COVID-19 Vaccine Dashboard is updated to more accurately reflect the number of people who are partially and fully vaccinated in each county outside of Philadelphia, along with the demographics of those receiving vaccine. For state-to-state comparisons refer to the CDC vaccine data tracker located here: https://covid.cdc.gov/covid-data-tracker/#county-view

Data only includes information reported to PA-SIIS, the Pennsylvania Statewide Immunization Information System.

The Federal Pharmacy Partnership for Long-Term Care (LTC) Program was a partnership between CDC and CVS, Walgreens, and Managed Health Care Associates, Inc. The program offered on-site COVID-19 vaccination services for residents of nursing homes and assisted living facilities. The Federal Pharmacy Partnership for LTC Program was in effect after vaccines became available to April 23, 2021. This is the historical archived data related to the LTC Program and represents data that was shown on COVID Data Tracker through September 30, 2021. Twelve variables that provided data on residents and staff vaccinated through the program were removed from the COVID-19 Vaccinations in the United States,Jurisdiction dataset. LTC was removed as an option from the location variable in the following datasets: COVID-19 Vaccinations in the United States,Jurisdiction and COVID-19 Vaccination Trends in the United States,National and Jurisdictional.

Weekly updates have finished with the June 28th update. This dataset contains aggregate data by zip code of residence and by race for individuals that received a COVID vaccination. Data includes counts of individuals who received a vaccine dose that provides partial coverage against the disease and counts of individuals that received a vaccine dose that provides full coverage against the disease. Suppression applies for quantities less than 5.
Effective 7/9/2021, the COVID-19 Vaccine Dashboard is updated to more accurately reflect the number of people who are partially and fully vaccinated in each county outside of Philadelphia, along with the demographics of those receiving vaccine. For state-to-state comparisons refer to the CDC vaccine data tracker located here: https://covid.cdc.gov/covid-data-tracker/#county-view

Data only includes information reported to PA-SIIS, the Pennsylvania Statewide Immunization Information System.

Weekly updates have finished with the June 28th update.

This dataset contains aggregate data by zip code of residence for the age groups of individuals that received a COVID vaccination. Data includes counts of individuals who received a vaccine dose that provides partial coverage against the disease and counts of individuals that received a vaccine dose that provides full coverage against the disease. Age groups are presented in 5-year brackets. Suppression applies for quantities less than 5 and records under review.

Data only includes information reported to PA-SIIS, the Pennsylvania Statewide Immunization Information System.

Effective 7/9/2021, the COVID-19 Vaccine Dashboard is updated to more accurately reflect the number of people who are partially and fully vaccinated in each county outside of Philadelphia, along with the demographics of those receiving vaccine. For state-to-state comparisons refer to the CDC vaccine data tracker located here: https://covid.cdc.gov/covid-data-tracker/#county-view

Splitgraph serves as an HTTP API that lets you run SQL queries directly on this data to power Web applications. For example:

See the Splitgraph documentation for more information.

These archived cumulative COVID-19 vaccination coverage estimates are for persons who were pregnant anytime from December 20, 2020, to January 20, 2022, and received at least 1 dose of COVID-19 vaccine during pregnancy based on data from the Vaccine Safety Datalink*. As of January 20, 2022, after moving to reporting weekly estimates, the figures on https://covid.cdc.gov/covid-data-tracker/#vaccinations-pregnant-women no longer present cumulative estimates, and these archived data are no longer updated.

For these cumulative data, on December 15, 2021, an error was identified where pregnant people who had received an additional or booster dose of a COVID-19 vaccine were not included in the coverage estimates. After correcting the error, coverage estimates for the week of December 11, 2021, increased overall and by race/ethnicity. The persons that were inadvertently excluded have been counted in the December 11, 2021, estimates. Prior weeks’ estimates have not been updated.

CDC is collaborating with Vitalant Research Institute, American Red Cross, and Westat Inc. to conduct a nationwide COVID-19 seroprevalence survey of blood donors. De-identified blood samples are tested for antibodies to SARS-CoV-2 to better understand the percentage of people in the United States who have antibodies against SARS-CoV-2 (the virus that causes COVID-19) and to track how this percentage changes over time. Both SARS-CoV-2 infection and COVID-19 vaccines currently used in the United States result in production of anti-spike (anti-S) antibodies but only infection results in production of anti-nucleocapsid (anti-N) antibodies. Infection-induced seroprevalence estimates the proportion of the population with antibody evidence of previous SARS-CoV-2 infection and refers to the percent of the population with anti-nucleocapsid antibodies. Combined infection-Induced and Vaccination-Induced seroprevalence estimates the proportion of the population with antibody evidence of previous SARS-CoV-2 infection, COVID-19 vaccination, or both, and refers to the percent of the population that has anti-spike antibodies, anti-nucleocapsid antibodies, or both. This link connects to a webpage that displays the data from the Nationwide Blood Donor Seroprevalence Survey. It offers an interactive visualization available at https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022

Note: Reporting of new COVID-19 Case Surveillance data will be discontinued July 1, 2024, to align with the process of removing SARS-CoV-2 infections (COVID-19 cases) from the list of nationally notifiable diseases. Although these data will continue to be publicly available, the dataset will no longer be updated.

Authorizations to collect certain public health data expired at the end of the U.S. public health emergency declaration on May 11, 2023. The following jurisdictions discontinued COVID-19 case notifications to CDC: Iowa (11/8/21), Kansas (5/12/23), Kentucky (1/1/24), Louisiana (10/31/23), New Hampshire (5/23/23), and Oklahoma (5/2/23). Please note that these jurisdictions will not routinely send new case data after the dates indicated. As of 7/13/23, case notifications from Oregon will only include pediatric cases resulting in death.

This case surveillance public use dataset has 19 elements for all COVID-19 cases shared with CDC and includes demographics, geography (county and state of residence), any exposure history, disease severity indicators and outcomes, and presence of any underlying medical conditions and risk behaviors.

Currently, CDC provides the public with three versions of COVID-19 case surveillance line-listed data: this 19 data element dataset with geography, a 12 data element public use dataset, and a 33 data element restricted access dataset.

The following apply to the public use datasets and the restricted access dataset:

• Data elements can be found on the COVID-19 case report form located at www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf.
• Data are considered provisional by CDC and are subject to change until the data are reconciled and verified with the state and territorial data providers.
• Some data are suppressed to protect individual privacy.
• Datasets will include all cases with the earliest date available in each record (date received by CDC or date related to illness/specimen collection) at least 14 days prior to the creation of the current datasets. This 14-day lag allows case reporting to be stabilized and ensure that time-dependent outcome data are accurately captured.
• Datasets are updated monthly.
• Datasets are created using CDC’s Policy on Public Health Research and Nonresearch Data Management and Access and include protections designed to protect individual privacy.
• For more information about data collection and reporting, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/about-us-cases-deaths.html.
• For more information about the COVID-19 case surveillance data, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/faq-surveillance.html
  

Overview

The COVID-19 case surveillance database includes individual-level data reported to U.S. states and autonomous reporting entities, including New York City and the District of Columbia (D.C.), as well as U.S. territories and affiliates. On April 5, 2020, COVID-19 was added to the Nationally Notifiable Condition List and classified as “immediately notifiable, urgent (within 24 hours)” by a Council of State and Territorial Epidemiologists (CSTE) Interim Position Statement (Interim-20-ID-01). CSTE updated the position statement on August 5, 2020, to clarify the interpretation of antigen detection tests and serologic test results within the case classification (Interim-20-ID-02). The statement also recommended that all states and territories enact laws to make COVID-19 reportable in their jurisdiction, and that jurisdictions conducting surveillance should submit case notifications to CDC. COVID-19 case surveillance data are collected by jurisdictions and reported voluntarily to CDC.

For more information: NNDSS Supports the COVID-19 Response | CDC.

COVID-19 Case Reports COVID-19 case reports are routinely submitted to CDC by public health jurisdictions using nationally standardized case reporting forms. On April 5, 2020, CSTE released an Interim Position Statement with national surveillance case definitions for COVID-19. Current versions of these case definitions are available at: https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2021/. All cases reported on or after were requested to be shared by public health departments to CDC using the standardized case definitions for lab-confirmed or probable cases. On May 5, 2020, the standardized case reporting form was revised. States and territories continue to use this form.

Data are Considered Provisional

• The COVID-19 case surveillance data are dynamic; case reports can be modified at any time by the jurisdictions sharing COVID-19 data with CDC. CDC may update prior cases shared with CDC based on any updated information from jurisdictions. For instance, as new information is gathered about previously reported cases, health departments provide updated data to CDC. As more information and data become available, analyses might find changes in surveillance data and trends during a previously reported time window. Data may also be shared late with CDC due to the volume of COVID-19 cases.
• Annual finalized data: To create the final NNDSS data used in the annual tables, CDC works carefully with the reporting jurisdictions to reconcile the data received during the year until each state or territorial epidemiologist confirms that the data from their area are correct.

Access Addressing Gaps in Public Health Reporting of Race and Ethnicity for COVID-19, a report from the Council of State and Territorial Epidemiologists, to better understand the challenges in completing race and ethnicity data for COVID-19 and recommendations for improvement.

Data Limitations

To learn more about the limitations in using case surveillance data, visit FAQ: COVID-19 Data and Surveillance.

Data Quality Assurance Procedures

CDC’s Case Surveillance Section routinely performs data quality assurance procedures (i.e., ongoing corrections and logic checks to address data errors). To date, the following data cleaning steps have been implemented:

• Questions that have been left unanswered (blank) on the case report form are reclassified to a Missing value, if applicable to the question. For example, in the question "Was the individual hospitalized?" where the possible answer choices include "Yes," "No," or "Unknown," the blank value is recoded to "Missing" because the case report form did not include a response to the question.
• Logic checks are performed for date data. If an illogical date has been provided, CDC reviews the data with the reporting jurisdiction. For example, if a symptom onset date in the future is reported to CDC, this value is set to null until the reporting jurisdiction updates the date appropriately.
• Additional data quality processing to recode free text data is ongoing. Data on symptoms, race, ethnicity, and healthcare worker status have been prioritized.

Data Suppression

To prevent release of data that could be used to identify people, data cells are suppressed for low frequency (<11 COVID-19 case records with a given values). Suppression includes low frequency combinations of case month, geographic characteristics (county and state of residence), and demographic characteristics (sex, age group, race, and ethnicity). Suppressed values are re-coded to the NA answer option; records with data suppression are never removed.

Additional COVID-19 Data

COVID-19 data are available to the public as summary or aggregate count files, including total counts of cases and deaths by state and by county. These and other COVID-19 data are available from multiple public locations: COVID Data Tracker; United States COVID-19 Cases and Deaths by State; COVID-19 Vaccination Reporting Data Systems; and COVID-19 Death Data and Resources.

Notes:

March 1, 2022: The "COVID-19 Case Surveillance Public Use Data with Geography" will be updated on a monthly basis.

April 7, 2022: An adjustment was made to CDC’s cleaning algorithm for COVID-19 line level case notification data. An assumption in CDC's algorithm led to misclassifying deaths that were not COVID-19 related. The algorithm has since been revised, and this dataset update reflects corrected individual level information about death status for all cases collected to date.

June 25, 2024: An adjustment